Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 2656 AL 2670

From structure to clinic: Design of a muscarinic M1 receptor agonist with potential to treatment of Alzheimer's disease

Brown AJH, Bradley SJ, Marshall FH, Brown GA, Bennett KA, Brown J, Cansfield JE, Cross DM, de Graaf C, Hudson BD, Dwomoh L, Dias JM, Errey JC, Hurrell E, Liptrot J, Mattedi G, Molloy C, Nathan PJ, Okrasa K, Osborne G, Patel JC, Pickworth M, Robertson N, Shahabi S, Bundgaard C, Phillips K, Broad LM, Goonawardena AV, Morairty SR, Browning M, Perini F, Dawson GR, Deakin JFW, Smith RT, Sexton PM, Warneck J, Vinson M, Tasker T, Tehan BG, Teobald B, Christopoulos A, Langmead CJ, Jazayeri A, Cooke RM, Rucktooa P, Congreve MS, Weir M, Tobin AB.

Cell. 2021 Nov 24;184(24):5886-5901.e22. doi: 10.1016/j.cell.2021.11.001.

The efficacy of psychological interventions for depressed primary caregivers of patients with Alzheimer's disease: A systematic review and meta-analysis

Liu X, Wang Y, Wang S.

J Nurs Scholarsh. 2022 May;54(3):355-366. doi: 10.1111/jnu.12742. Epub 2021 Nov 29.

Self-efficacy in controlling upsetting thoughts, but not positive gains, mediates the effects of benefit-finding group intervention for Alzheimer family caregivers

Cheng ST, Chan WC, Fung HH, Lam LCW.

Psychol Aging. 2022 Sep;37(6):766-775. doi: 10.1037/pag0000654. Epub 2021 Nov 29.

Dementia with non-convulsive seizures: a case report

Chen YS, Chen TS, Huang CW.

J Int Med Res. 2021 Dec;49(12):3000605211062453. doi: 10.1177/03000605211062453.

Repurposing Antihypertensive Drugs for the Management of Alzheimer's Disease

Law CSW, Yeong KY.

Curr Med Chem. 2021;28(9):1716-1730. doi: 10.2174/0929867327666200312114223.

Connecting Mind-Body Therapy-Mediated Effects to Pathological Features of Alzheimer's Disease

Hüttenrauch M, Lopez-Noguerola JS, Castro-Obregón S.

J Alzheimers Dis. 2021;82(s1):S65-S90. doi: 10.3233/JAD-200743.

Implementing Delirium Prevention in the Era of COVID-19

Radhakrishnan NS, Mufti M, Ortiz D, Maye ST, Melara J, Lim D, Rosenberg EI, Price CC.

J Alzheimers Dis. 2021;79(1):31-36. doi: 10.3233/JAD-200696.

Update and Potential Opportunities in CBP [Cyclic Adenosine Monophosphate (cAMP) Response Element-Binding Protein (CREB)-Binding Protein] Research Using Computational Techniques

Akinsiku OE, Soremekun OS, Soliman MES.

Protein J. 2021 Feb;40(1):19-27. doi: 10.1007/s10930-020-09951-8. Epub 2021 Jan 4.

Change in cognitive function according to cholinesterase inhibitor use and amyloid PET positivity in patients with mild cognitive impairment

Pyun JM, Ryoo N, Park YH, Kim S.

Alzheimers Res Ther. 2021 Jan 5;13(1):10. doi: 10.1186/s13195-020-00749-5.

Direct and indirect neurological, cognitive, and behavioral effects of COVID-19 on the healthy elderly, mild-cognitive-impairment, and Alzheimer's disease populations

Iodice F, Cassano V, Rossini PM.

Neurol Sci. 2021 Feb;42(2):455-465. doi: 10.1007/s10072-020-04902-8. Epub 2021 Jan 7.

Hypertriglyceridemia and Alzheimer Disease: Opening the Mind to New Therapeutic Opportunities

Watts GF, Mamo JCL.

Clin Chem. 2021 Jan 8;67(1):6-8. doi: 10.1093/clinchem/hvaa294.

Crocus Sativus L. (Saffron) in Alzheimer's Disease Treatment: Bioactive Effects on Cognitive Impairment

D'Onofrio G, Nabavi SM, Sancarlo D, Greco A, Pieretti S.

Curr Neuropharmacol. 2021;19(9):1606-1616. doi: 10.2174/1570159X19666210113144703.

New approaches to symptomatic treatments for Alzheimer's disease

Cummings J.

Mol Neurodegener. 2021 Jan 13;16(1):2. doi: 10.1186/s13024-021-00424-9.

The Fragility of Temporal Memory in Alzheimer's Disease

Park JH, Lee SA.

J Alzheimers Dis. 2021;79(4):1631-1646. doi: 10.3233/JAD-200892.

Nanotechnology Therapy for Alzheimer's Disease Memory Impairment Attenuation

Ribarič S.

Int J Mol Sci. 2021 Jan 22;22(3):1102. doi: 10.3390/ijms22031102.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias